Nevro Corp. Shares Acquisition Plans and Financial Overview

Nevro Corp. Financial Results and Strategic Acquisition Plans

Nevro Corp. (NYSE: NVRO), a leader in innovative medical device solutions aimed at alleviating chronic pain, recently announced its financial results for the fourth quarter and the entire fiscal year of 2024. The company continues to focus on enhancing its balance sheet while aligning its growth strategy with the planned acquisition by Globus Medical (NYSE: GMED).

Strategic Acquisition Announcement

On a significant note, Nevro Corp. and Globus Medical revealed a definitive agreement for an acquisition valued at approximately $250 million, with each share priced at $5.85. This strategic move is set to finalize in the second quarter of 2025, pending approval from shareholders, along with regulatory conditions. Nevro’s president and CEO, Kevin Thornal, expressed optimism about the merger, highlighting the potential to enhance their mission of alleviating chronic pain for patients globally.

2024 Business Highlights

Throughout the quarter, Nevro accomplished several notable releases and improvements:

• Nevro successfully rolled out full market availability of the HFX iQ™ device, featuring the innovative HFX AdaptivAI™ technology aimed at delivering personalized pain management.
• In January 2025, the HFX iQ spinal cord stimulation (SCS) system was launched in select European markets after securing CE Mark certification in November 2024.
• Recent research published in the Journal of Pain Research emphasized the efficacy of Nevro's 10 kHz high-frequency SCS therapy in providing durable pain relief, particularly for patients suffering from diabetic neuropathy.
• Further findings shared in Medical Devices: Evidence and Research illustrated the superior advantages of Nevro's SI Joint Fusion System over traditional fixation methods.

Fourth-Quarter 2024 Financial Results

Nevro reported worldwide revenues of $105.5 million for the fourth quarter of 2024, marking a decrease of 9.1% from $116.2 million in the same quarter of 2023. U.S. revenues account for $91.4 million, down from $101.5 million in the prior year. Meanwhile, international revenue saw a slight dip to $14.1 million amidst competitive market conditions.

Examining gross profits, Nevro recorded a gross profit of $65.9 million, equating to a gross margin of 62.5%, which is lower than the 70.1% margin from the previous year. Operating expenses surged to $117.3 million, fueled by a significant goodwill impairment charge and other related costs.

Full-Year Financial Overview

Over the course of 2024, Nevro’s total revenue reached $408.5 million, down 3.9% year-on-year. The company also noted an adjusted EBITDA loss of $13.6 million, a slight improvement from a loss of $17.7 million recorded in 2023. Nevro remains committed to improving operational efficiency and exploring avenues for revenue growth as part of its forward-looking strategy, especially in preparation for the acquisition by Globus Medical.

Key Insights from Nevro’s Financial Guidance

Due to the ongoing acquisition process, Nevro will not be issuing further guidance for the fiscal year 2025. The focus remains on ensuring a seamless transition and maximizing value for shareholders while maintaining operational momentum.

About Nevro Corp.

Nevro Corp. is dedicated to providing advanced solutions for chronic pain management. The company’s flagship HFX spinal cord stimulation platform is known for its effectiveness in treating chronic pain, which includes services tailored for patients dealing with sacroiliac joint pain and diabetic neuropathy. The acquisition by Globus Medical is anticipated to enhance Nevro’s capabilities in this vital area.

Investors can find vital information about Nevro in the "Investor Relations" section of its official website.

Frequently Asked Questions

What is the significance of the Globus Medical acquisition for Nevro?

The acquisition is expected to enhance Nevro’s capabilities in pain management, allowing for greater resource utilization and clinical synergies.

How did Nevro’s revenues change in 2024?

Nevro experienced a 3.9% decrease in total revenue for 2024 compared to the previous year, reflecting challenges in the market.

What products does Nevro offer for chronic pain management?

Nevro’s HFX spinal cord stimulation platform, including the HFX iQ system, is notable for its advanced pain management technology and support services.

What challenges did Nevro face in Q4 of 2024?

Major challenges included decreased revenues and increased operating expenses, particularly linked to an impairment charge impacting profitability.

What could investors expect from Nevro moving forward?

Investors can anticipate enhanced operational processes post-acquisition, aiming for improved financial health and product offerings in pain management.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.